These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. Wimalawansa S, Chapa T, Fang L, Yallampalli C, Simmons D, Wimalawansa S. J Bone Miner Res; 2000 Jun; 15(6):1119-25. PubMed ID: 10841180 [Abstract] [Full Text] [Related]
6. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465 [Abstract] [Full Text] [Related]
7. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Iwaniec UT, Samnegård E, Cullen DM, Kimmel DB. Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618 [Abstract] [Full Text] [Related]
13. Additional weight bearing during exercise and estrogen in the rat: the effect on bone mass, turnover, and structure. Tromp AM, Bravenboer N, Tanck E, Oostlander A, Holzmann PJ, Kostense PJ, Roos JC, Burger EH, Huiskes R, Lips P. Calcif Tissue Int; 2006 Dec; 79(6):404-15. PubMed ID: 17160577 [Abstract] [Full Text] [Related]
16. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats. Ke HZ, Crawford DT, Qi H, Pirie CM, Simmons HA, Chidsey-Frink KL, Chen HK, Jee WS, Thompson DD. Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783 [Abstract] [Full Text] [Related]